专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US5665482A Fluorite structure type ceria type solid electrolyte 失效
标题翻译：萤石结构型二氧化铈型固体电解质
公开(公告)号：US5665482A
公开(公告)日：1997-09-09
申请号：US582417
申请日：1996-01-03
申请人： Toshiyuki Mori , Hideto Kuramochi , Hiroshi Yamamura
发明人： Toshiyuki Mori , Hideto Kuramochi , Hiroshi Yamamura
IPC分类号： C04B35/50 , H01M8/12 , H01M8/10
CPC分类号： C04B35/50 , H01M8/126 , Y02E60/525 , Y02P70/56
摘要： A defective fluorite structure type solid electrolyte of the following formula (1):{(M.sub.1-a A.sub.a).sub.x Ce.sub.1-x }O.sub.2-y (1)wherein M is a trivalent rare earth element other than Ce, A is a monovalent alkali metal or a bivalent alkaline earth metal, and a, x and y are 0
摘要翻译：下式（1）的有缺陷的萤石结构型固体电解质：{（M1-aAa）xCe1-x} O2-y（1）其中M是Ce以外的三价稀土元素，A是一价碱金属或二价碱土金属，a，x和y分别为0

2. 发明授权

US5204077A Pollucite crystalline powders with low thermal expansion coefficients and methods for their preparation 失效
标题翻译：具有低热膨胀系数的POLLUCITE CRYSTALLIL粉末及其制备方法
公开(公告)号：US5204077A
公开(公告)日：1993-04-20
申请号：US760136
申请日：1991-09-16
申请人： Toshiyuki Mori , Hiroshi Yamamura , Takashi Mitamura , Hidehiko Kobayashi
发明人： Toshiyuki Mori , Hiroshi Yamamura , Takashi Mitamura , Hidehiko Kobayashi
IPC分类号： C01F17/00 , C01B33/26 , C04B35/18
CPC分类号： C01B33/26
摘要： A pollucite powder consisting essentially of a pollucite phase and having an Al.sub.2 O.sub.3 /SiO.sub.2 molar ratio of from 0.21 to 0.25 and a Cs.sub.2 O/SiO.sub.2 molar ratio of from 0.19 to 0.22.

3. 发明授权

US5250480A Method for preparing zircon powder 失效
标题翻译：制备锆石粉的方法
公开(公告)号：US5250480A
公开(公告)日：1993-10-05
申请号：US985455
申请日：1992-12-03
申请人： Hirokuni Hoshino , Toshiyuki Mori , Hiroshi Yamamura , Naoki Kosugi
发明人： Hirokuni Hoshino , Toshiyuki Mori , Hiroshi Yamamura , Naoki Kosugi
IPC分类号： C01B33/20 , C04B35/48
CPC分类号： C01B33/20
摘要： A method for preparing zircon powder, which comprises mixing (1) silica sol and (2) an aqueous zirconium oxychloride solution having a concentration which would be from 0.1 to 2 mols/l after mixed with the silica sol, in a SiO.sub.2 /ZrO.sub.2 molar ratio of from 0.95 to 1.10, heating the mixture to hydrolyze the zirconium oxychloride, followed by dehydration treatment to obtain a powder, heating the powder from room temperature to a calcination temperature over a period of from 0.7 to 30 hours and calcining the powder at a temperature of from 1,200.degree. to 1,400.degree. C. for a period of time satisfying the relation of:t.gtoreq.116-0.08Twhere t is the calcination time (hr) and T is the calcination temperature (.degree.C.), or heating the powder from room temperature to a calcination temperature over a period of from 0.8 to 70 hours and calcining the powder at a temperature higher than 1,400.degree. C. and not higher than 1,700.degree. C. for a period of time satisfying the relation of:t.gtoreq.18-0.01Twhere t is the calcination time (hr) and T is the calcination temperature (.degree.C.).
摘要翻译：一种制备锆石粉末的方法，其包括在SiO 2 / ZrO 2摩尔中混合（1）硅溶胶和（2）与硅溶胶混合后浓度为0.1至2摩尔/升的氯氧化锆水溶液比例为0.95〜1.10，加热混合物水解氯氧化锆，然后进行脱水处理，得到粉末，将粉末从室温加热至煅烧温度，时间为0.7〜30小时，并将粉末在温度为1200〜1400℃，时间满足以下关系：t> / = 116-0.08T其中t为煅烧时间（hr），T为煅烧温度（℃），或将粉末从室温加热至煅烧温度0.8〜70小时，并在高于1400℃，不高于1700℃的温度下煅烧粉末，时间满足以下关系： t> / = 18-0.01T其中t是煅烧时间（hr），T为煅烧温度（℃）。

4. 发明授权

US08664221B2 Method for treating an inflammatory disease by administering a 1,2,3,4- tetrahydroquinoxaline compound containing a phenyl group having a sulfonic acid ester structure introduced therein as a substituent 失效
标题翻译：通过给予含有其中引入了磺酸酯结构的苯基的1,2,3,4-四氢喹喔啉化合物作为取代基来治疗炎性疾病的方法
公开(公告)号：US08664221B2
公开(公告)日：2014-03-04
申请号：US13063186
申请日：2009-09-11
申请人： Masatomo Kato , Miwa Takai , Takahiro Matsuyama , Tatsuji Kurose , Yumi Hagiwara , Kenji Oki , Mamoru Matsuda , Toshiyuki Mori
发明人： Masatomo Kato , Miwa Takai , Takahiro Matsuyama , Tatsuji Kurose , Yumi Hagiwara , Kenji Oki , Mamoru Matsuda , Toshiyuki Mori
IPC分类号： A01N43/58 , A01N43/60 , A61K31/495 , A61K31/50 , C07D241/36
CPC分类号： C07D295/135 , A61K31/498 , A61K31/5377 , C07D241/44 , C07D409/12
摘要： The object aims to find a novel pharmacological activity of a novel 1,2,3,4-tetrahydroquinoxaline derivative which contains, as a substituent, a phenyl group having a sulfonic acid ester structure introduced therein. A compound represented by general formula (1) or a salt thereof is useful as a glucocorticoid receptor agonist, particularly as a therapeutic agent for diseases against which a glucocorticoid receptor agonist (e.g., a steroid) is believed to be effective, such as inflammatory bone/joint diseases, inflammatory ophthalmic diseases (inflammatory ophthalmic diseases in the anterior or posterior segment of an eye). R1 represents a group represented by general formula (2a), (3a), (4a) or (5a); R2 represents a lower alkyl group which may have a substituent, a lower cycloalkyl group which may have a substituent, or the like; R3 represents a lower alkyl group; R4, R5, R6 or R7 represent a halogen atom, a lower alkyl group which may have a substituent, a hydroxy group, a lower alkoxy group which may have a substituent, or the like; and m, n, p or q represents a number of 0, 1 or 2.
摘要翻译：本发明的目的在于找到引入其中具有磺酸酯结构的苯基作为取代基的新的1,2,3,4-四氢喹喔啉衍生物的新药理活性。由通式（1）表示的化合物或其盐可用作糖皮质激素受体激动剂，特别是作为糖皮质激素受体激动剂（例如类固醇）被认为有效的疾病的治疗剂，例如炎性骨 /关节疾病，炎症性眼部疾病（眼睛前部或后部的炎症性眼部疾病）。 R1表示通式（2a），（3a），（4a）或（5a）表示的基团。 R 2表示可以具有取代基的低级烷基，可以具有取代基的低级环烷基等。 R3表示低级烷基; R4，R5，R6或R7表示卤素原子，可以具有取代基的低级烷基，羟基，可以具有取代基的低级烷氧基等; m，n，p或q表示0,1或2的数。

5. 发明授权

US08551991B2 1,2,3,4-tetrahydroquinoxaline derivative having glucocorticoid receptor binding activity 有权
标题翻译：具有糖皮质激素受体结合活性的1,2,3,4-四氢喹喔啉衍生物
公开(公告)号：US08551991B2
公开(公告)日：2013-10-08
申请号：US12225010
申请日：2007-03-14
申请人： Mamoru Matsuda , Toshiyuki Mori , Kenji Kawashima , Minoru Yamamoto , Masatomo Kato , Miwa Takai , Masato Nagatsuka , Sachiko Kobayashi
发明人： Mamoru Matsuda , Toshiyuki Mori , Kenji Kawashima , Minoru Yamamoto , Masatomo Kato , Miwa Takai , Masato Nagatsuka , Sachiko Kobayashi
IPC分类号： A61K31/535 , A61K31/44 , A01N43/40
CPC分类号： C07D241/46 , C07D241/44 , C07D401/12 , C07D401/14 , C07D405/12 , C07D409/12 , C07D409/14 , C07D413/12 , C07D417/12 , C07D417/14
摘要： An object of the present invention is to synthesize a novel 1,2,3,4-tetrahydroquinoxaline derivative represented by formula (1) and to find a pharmacological action of the derivative. In the formula, the R1 represents a halogen, an alkyl, cycloalkyl, aryl or heterocyclic group, or the like; p represents 0 to 5; R2 represents a halogen, an alkyl, hydroxyl or alkoxy group, or the like; q represents 0 to 2; R3 represents hydrogen, an alkyl, alkenyl, alkylcarbonyl or arylcarbonyl group, or the like; R4 and R5 independently represent hydrogen, a halogen, an alkyl, alkenyl, alkynyl, cycloalkyl, aryl or heterocyclic group, or the like; R6 represents hydrogen, an alkyl, alkenyl, alkynyl, cycloalkyl, aryl or heterocyclic group, or the like; A represents an alkylene; R7 represents OR8, NR8R9, SR8, S(O)R8, S(O)2R8; and X represents O or S.
摘要翻译：本发明的目的是合成由式（1）表示的新型1,2,3,4-四氢喹喔啉衍生物，并找到该衍生物的药理学作用。在该式中，R 1表示卤素，烷基，环烷基，芳基或杂环基等; p表示0〜5; R2表示卤素，烷基，羟基或烷氧基等; q表示0〜2; R3表示氢，烷基，烯基，烷基羰基或芳基羰基等; R4和R5独立地表示氢，卤素，烷基，烯基，炔基，环烷基，芳基或杂环基等; R6表示氢，烷基，烯基，炔基，环烷基，芳基或杂环基等; A表示亚烷基; R 7表示OR 8，NR 8 R 9，SR 8，S（O）R 8，S（O）而X代表O或S.

6. 发明授权

US08426406B2 Glucocorticoid receptor agonist comprising 2,2,4-trimethyl-6-phenyl-1,2-dihydroquinoline derivatives having substituted oxy group 有权
标题翻译：糖皮质激素受体激动剂包含具有取代氧基的2,2,4-三甲基-6-苯基-1,2-二氢喹啉衍生物
公开(公告)号：US08426406B2
公开(公告)日：2013-04-23
申请号：US12992237
申请日：2009-05-12
申请人： Masatomo Kato , Miwa Takai , Takahiro Matsuyama , Tatsuji Kurose , Yumi Hagiwara , Mamoru Matsuda , Toshiyuki Mori , Kenji Imoto , Atsuyoshi Dota
发明人： Masatomo Kato , Miwa Takai , Takahiro Matsuyama , Tatsuji Kurose , Yumi Hagiwara , Mamoru Matsuda , Toshiyuki Mori , Kenji Imoto , Atsuyoshi Dota
IPC分类号： A61K31/5377 , A61K31/47 , A61K31/4709 , A61K31/506
CPC分类号： A61K31/47 , A61K31/4709 , A61K31/506 , A61K31/5377 , C07D215/14 , C07D401/12 , C07D405/12 , C07D409/12 , C07D409/14 , C07D413/12 , C07D417/12 , C07D417/14
摘要： The present invention is related to glucocorticoid receptor agonists comprised of a compound represented by formula (1) which is 2,2,4-trimethyl-6-phenyl-1,2-dihydroquinoline derivative or a salt thereof and novel pharmacological effects of the glucocorticoid receptor agonists. In the formula (1), R1 represents formula (2a), (3a), (4a) or (5a); R2 represents —(CO)—R8, —(CO)O—R9, or the like; R2—O— is substituted at the 4- or -5-position of benzene ring A; R3 represents a lower alkyl group; R4, R5, R6 or R7 represents a halogen atom, a lower alkyl group which may have a substituent, or the like; m, n, p or q represents 0, 1 or the like; R8, R9 or the like represents a lower alkyl group which may have a substituent, a lower alkenyl group, or the like.
摘要翻译：本发明涉及由式（1）表示的化合物（其为2,2,4-三甲基-6-苯基-1,2-二氢喹啉衍生物或其盐）的糖皮质激素受体激动剂和糖皮质激素的新药理作用受体激动剂。在式（1）中，R 1表示式（2a），（3a），（4a）或（5a） R2表示 - （CO）-R8， - （CO）O-R9等; R2-O-在苯环A的4-或5-位被取代; R3表示低级烷基; R4，R5，R6或R7表示卤原子，可以具有取代基的低级烷基等; m，n，p或q表示0,1等; R8，R9等表示可以具有取代基的低级烷基，低级烯基等。

7. 发明授权

US08008496B2 1,2-dihydroquinoline derivative having substituted phenylchalcogeno lower alkyl group and ester-introduced phenyl group as substituents 有权
标题翻译：具有取代的苯基硫代低级烷基和酯引入的苯基作为取代基的1,2-二氢喹啉衍生物
公开(公告)号：US08008496B2
公开(公告)日：2011-08-30
申请号：US12312392
申请日：2007-11-14
申请人： Mamoru Matsuda , Masato Nagatsuka , Toshiyuki Mori , Sachiko Kobayashi , Masatomo Kato , Miwa Takai
发明人： Mamoru Matsuda , Masato Nagatsuka , Toshiyuki Mori , Sachiko Kobayashi , Masatomo Kato , Miwa Takai
IPC分类号： C07D215/38
CPC分类号： C07D401/12 , C07D215/14 , C07D405/12 , C07D409/12 , C07D409/14 , C07D417/12
摘要： The compounds represented in general formula (1) and a salt thereof are useful for glucocorticoid receptor modulator. The R1 represents a hydrogen atom or a lower alkyl group; R2 represents a hydrogen atom or a lower alkyl group; R3 and R4 may be the same or different and represent a hydrogen atom or a lower alkyl group; R5 represents a hydrogen atom or a lower alkyl group; R6 represents a halogen atom, a lower alkyl group, a hydroxy group, a lower alkoxy group or a nitro group; X represents —C(O)—, —C(O)NR8—, —S(O)2— and the like; R7 and/or R8 may be the same or different and represent a hydrogen atom, a lower alkyl group which may have a substituent, an aryl group which may have a substituent, a heterocyclic group which may have a substituent, a lower alkoxy group which may have a substituent and the like; Y represents a lower alkylene group; Z represents a chalcogen atom; and P represents 0, 1, 2 or 3.
摘要翻译：通式（1）表示的化合物及其盐可用于糖皮质激素受体调节剂。 R1表示氢原子或低级烷基; R2表示氢原子或低级烷基; R 3和R 4可以相同或不同，表示氢原子或低级烷基; R5表示氢原子或低级烷基; R6表示卤素原子，低级烷基，羟基，低级烷氧基或硝基; X表示-C（O） - ， - C（O）NR 8 - ， - S（O）2等） R 7和/或R 8可以相同或不同，表示氢原子，可以具有取代基的低级烷基，可以具有取代基的芳基，可以具有取代基的杂环基，低级烷氧基可以具有取代基等; Y表示低级亚烷基; Z表示硫属原子; P表示0,1,2或3。

8. 发明申请

US20100056504A1 NOVEL 1,2-DIHYDROQUINOLINE DERIVATIVE HAVING SUBSTITUTED PHENYLCHALCOGENO LOWER ALKYL GROUP AND ESTER- INTRODUCED PHENYL GROUP AS SUBSTITUENTS 有权
标题翻译：具有取代的苯乙烯基低级烷基的新的1,2-二氢喹啉衍生物和引入的苯基作为取代基
公开(公告)号：US20100056504A1
公开(公告)日：2010-03-04
申请号：US12312392
申请日：2007-11-14
申请人： Mamoru Matsuda , Masato Nagatsuka , Toshiyuki Mori , Sachiko Kobayashi , Masatomo Kato , Miwa Takai
发明人： Mamoru Matsuda , Masato Nagatsuka , Toshiyuki Mori , Sachiko Kobayashi , Masatomo Kato , Miwa Takai
IPC分类号： A61K31/541 , C07D279/06 , C07D413/12 , C07D215/38 , A61K31/47 , A61K31/5377 , A61P25/00
CPC分类号： C07D401/12 , C07D215/14 , C07D405/12 , C07D409/12 , C07D409/14 , C07D417/12
摘要： The compounds represented in general formula (1) and a salt thereof are useful for glucocorticoid receptor modulator. The R1 represents a hydrogen atom or a lower alkyl group; R2 represents a hydrogen atom or a lower alkyl group; R3 and R4 may be the same or different and represent a hydrogen atom or a lower alkyl group; R5 represents a hydrogen atom or a lower alkyl group; R6 represents a halogen atom, a lower alkyl group, a hydroxy group, a lower alkoxy group or a nitro group; X represents —C(O)—, —C(O)NR8—, —S(O)2— and the like; R7 and/or R8 may be the same or different and represent a hydrogen atom, a lower alkyl group which may have a substituent, an aryl group which may have a substituent, a heterocyclic group which may have a substituent, a lower alkoxy group which may have a substituent and the like; Y represents a lower alkylene group; Z represents a chalcogen atom; and P represents 0, 1, 2 or 3.
摘要翻译：通式（1）表示的化合物及其盐可用于糖皮质激素受体调节剂。 R1表示氢原子或低级烷基; R2表示氢原子或低级烷基; R 3和R 4可以相同或不同，表示氢原子或低级烷基; R5表示氢原子或低级烷基; R6表示卤素原子，低级烷基，羟基，低级烷氧基或硝基; X表示-C（O） - ， - C（O）NR 8 - ， - S（O）2等） R 7和/或R 8可以相同或不同，表示氢原子，可以具有取代基的低级烷基，可以具有取代基的芳基，可以具有取代基的杂环基，低级烷氧基可以具有取代基等; Y表示低级亚烷基; Z表示硫属原子; P表示0,1,2或3。

9. 发明申请

US20080154007A1 Cross-Linked Polymer Particle and Manufacturing Method Thereof 审中-公开
标题翻译：交联聚合物颗粒及其制造方法
公开(公告)号：US20080154007A1
公开(公告)日：2008-06-26
申请号：US11722877
申请日：2005-12-28
申请人： Toshiyuki Mori , Koji Fujita , Koshin Ushizaki
发明人： Toshiyuki Mori , Koji Fujita , Koshin Ushizaki
IPC分类号： C08F220/10
CPC分类号： B01J20/26 , A61M1/3679 , C08F2/20 , C08F8/12 , C08F218/08 , C08F226/02 , C08F226/06 , C08F265/06 , C08F2222/1013 , C08F220/28
摘要： Crosslinked polymer particles that are useful as an adsorbent, or carrier thereof, for treatment of a liquid containing physiological substance and/or cells, etc., such as body fluid, and that is reduced in the activation of complement system and leukocytes; and a process for producing polymer particles being useful as an adsorbent/treating material, or carrier thereof, for treatment of body fluid. In particular, there are provided crosslinked polymer particles comprising as a constituent a polymerization unit containing a vinyl alcohol unit and nitrogen-containing polymerization unit, wherein the content of nitrogen base on the whole weight of grains in the dry state as determined by elementary analysis is in the range of 7.0 to 13.0 weight %, and wherein the surface nitrogen content determined by X-ray photoelectron spectroscopy (XPS) is in the range of 5.0 to 15.0 at %. Further, there are provided crosslinked polymer particles of 50 to 3000 μm volume average particle diameter, of which ≧80 volume % particles have a diameter of 0.8 to 1.2 times the volume average particle diameter, obtained by first forming liquid drops of uniform diameter consisting of a monomer mixture in a dispersion medium and subsequently polymerizing the liquid drops under conditions avoiding cohesion or additional dispersion thereof, optionally further conducting treatment or modification; and is provided a relevant process for producing polymer particles.
摘要翻译：可用作吸附剂或其载体的交联聚合物颗粒，用于处理含有生理物质和/或细胞等的液体，例如体液，并且减少补体系统和白细胞的活化; 以及用于制备用作治疗体液的吸附剂/处理材料或其载体的聚合物颗粒的方法。特别地，提供了包含含有乙烯醇单元和含氮聚合单元的聚合单元作为组分的交联聚合物颗粒，其中通过元素分析确定的干燥状态下的整个颗粒重量中的氮碱含量为在7.0〜13.0重量％的范围内，通过X射线光电子能谱（XPS）测定的表面氮含量为5.0〜15.0原子％。此外，提供了50〜3000μm体积平均粒径的交联聚合物粒子，其中> = 80体积％的粒子的直径为体积平均粒径的0.8〜1.2倍，通过首先形成均匀直径的液滴得到，的分散介质中的单体混合物，随后在避免内聚或其另外分散的条件下聚合液滴，任选进一步进行处理或改性; 并提供了生产聚合物颗粒的相关方法。

10. 发明授权

US06765033B1 Expandable vinyl chloride resin composition 失效
标题翻译：可膨胀氯乙烯树脂组合物
公开(公告)号：US06765033B1
公开(公告)日：2004-07-20
申请号：US09622474
申请日：2000-08-17
申请人： Takenobu Sunagawa , Noriko Sakashita , Toshiyuki Mori , Akira Takaki
发明人： Takenobu Sunagawa , Noriko Sakashita , Toshiyuki Mori , Akira Takaki
IPC分类号： C08J908
CPC分类号： C08J9/0061 , C08J9/08 , C08J2327/06 , C08J2433/00 , C08L27/06 , C08L33/06 , C08L2666/04
摘要： An expandable vinyl chloride resin composition that the expansion ratio of a vinyl chloride resin can be greatly increased by the use of thermally decomposable inorganic blowing agents without the use of organic solvent blowing agents, and which comprises 100 parts by weight of a vinyl chloride resin, 5 to 30 parts by weight of, as a processing aid, a (meth)acrylic acid ester polymer having a specific viscosity of not less than 0.73 measured at 30° C. with respect to a solution of 0.1 g of the polymer dissolved in 100 ml of chloroform, and 2 to 25 parts by weight of a thermally decomposable inorganic blowing agent.
摘要翻译：通过使用可分解无机发泡剂而不使用有机溶剂发泡剂，氯乙烯树脂的膨胀比可以大大提高，并且包括100重量份的氯乙烯树脂，作为加工助剂的5〜30重量份作为加工助剂的（甲基）丙烯酸酯聚合物相对于溶解在100克中的聚合物的溶液，在30℃下测定的比粘度不低于0.73 氯仿和2〜25重量份的热分解无机发泡剂。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式